Hypochlorous Acid for Health & Longevity

Evidence Review created on 09/26/2026 using AI4L + evidence-mcp / Grok 4

Also known as: HOCl, Electrolyzed Water, Electrolyzed Oxidizing Water, Superoxidized Solution, Super-Oxidized Solution

Motivation

Hypochlorous acid is a weak chlorine chemical that immune cells release when they attack bacteria. Stabilized solutions are sold mainly as a wound rinse and an eyelid spray. For health- and longevity-oriented adults the question is whether this local germ-killing liquid can cut infections on those surfaces and calm inflammation that otherwise becomes a chronic problem.

Washing surgical wounds has used related chlorine solutions for about a century, first as harsher bleach-like liquids and later as milder products with controlled acidity. Modern use clusters in wound clinics and eyelid care. Claims that oral use slows aging came later and rest on reputation rather than on aging studies.

This review examines what hypochlorous acid is, where human studies show a local benefit, where they show harm or mix-ups with household bleach, and how product form, quality, and success are judged. It keeps the stabilized acid distinct from household bleach and local findings distinct from longevity claims.

Benefits - Risks - Protocol - Conclusion

Narrative reviews and expert commentaries that sketch hypochlorous acid (HOCl) as a topical antiseptic, not systematic reviews and not the reference sites in the next sections.

No substantial overview was found from Peter Attia, Andrew Huberman, Chris Kresser, Life Extension, or Lifespan.io. A FoundMyFitness story on saltwater nasal rinsing names hypochlorous acid once, as something airway cells make, and does not review the bottled acid, so it is not listed. Five clinical narrative reviews are used instead.

Grokipedia

Hypochlorous acid

Plain-language page on the chemistry, neutrophil production, and topical uses in wounds, eyes, and skin. It is not a critical appraisal of longevity claims.

Examine

Hypochlorous Acid

Short monograph that frames the acid as an immune-cell oxidant used as a disinfectant and sanitizer, which matches the evidence and is not a systemic longevity agent.

ConsumerLab

No dedicated ConsumerLab article on hypochlorous acid was found. The only on-site mention is a disinfectant note inside a coronavirus-cleaning answer, not a health monograph.

Systematic Reviews

Systematic reviews that isolate hypochlorous acid, as distinct from sodium hypochlorite bleach irrigants used in root-canal treatment, are scarce on PubMed.

No systematic review was found of harm from oral use, inhaled use, or lifespan. Safety of surgical irrigation is inside the Ayers synthesis. Tissue injury from concentrated sodium hypochlorite, the main mix-up risk, is unrepresented by a hypochlorous-acid-specific review.

Mechanism of Action

Hypochlorous acid is the chlorine oxidant neutrophils release when myeloperoxidase (MPO, the neutrophil enzyme that converts peroxide and chloride into this acid) acts on hydrogen peroxide and chloride. The acid–base constant (pKa) is about 7.5, so the undissociated acid predominates in mildly acidic solution and is more microbicidal than the hypochlorite ion that dominates in alkaline bleach. It is not a receptor drug. It oxidizes cysteine and methionine, amines, and nucleotides, which disrupts microbial proteins, membranes, and biofilm (a surface microbial film) rather than one enzyme (Ulfig & Leichert, 2021).

Mammalian cells are relatively spared at the tens to a few hundred parts per million used on surfaces, because glutathione (a cell antioxidant) and other thiols (sulfur groups) quench the acid on contact. Taurine chloramine, a longer-lived product, can dampen nuclear factor kappa B (NF-κB, a protein complex that turns on inflammatory genes). That is the proposed basis for calming redness beyond killing microbes. One account treats any clinical gain as antisepsis alone. Another adds an anti-inflammatory effect of the chloramine. Trials rarely separate the two.

Half-life in tissue is seconds. Organic matter consumes the acid at the surface, so there is no circulating half-life and no distribution of a parent molecule after topical use. Selectivity is for electron-rich sulfur and nitrogen groups. Clearance is reduction by glutathione and taurine, not cytochrome P450 (CYP, liver enzymes that clear many drugs). Formulas that add acetic acid are a different product and are flagged when a trial used them.

Historical Context & Evolution

Chlorine water was used as a disinfectant in the early nineteenth century. Dilute sodium hypochlorite entered surgery in the First World War as Dakin’s solution, developed by Henry Dakin with Alexis Carrel to irrigate (wash) contaminated wounds. That solution is alkaline hypochlorite, not the pH-controlled acid used now, and it irritated tissue more. The endogenous account came later. Myeloperoxidase was linked to hypochlorous acid inside neutrophils in the mid-twentieth century, which reframed the molecule as a host-defense chemical rather than only a cleaner.

From the 1990s, electrolysis of saline produced superoxidized or electrolyzed water, used first at scale in Japan and then in wound clinics as a ready irrigant (a rinse). Stabilization stretched shelf life from minutes to months and allowed eyelid, oral, and skin products. During the coronavirus pandemic the acid was widely adopted as a surface spray and, in some clinics, discussed as a mucosal antiseptic. None of that arc was a longevity program. Marketing that frames oral or inhaled use of the acid as a way to slow aging is recent and sits outside the wound, eye, and dental record. What changed is shelf stability and the settings of use, not a demonstration that the acid changes the rate of aging. Older alkaline solutions and newer stabilized acid are related chemistry with different tolerability, not one interchangeable drug whose early results were simply overturned.

Expected Benefits

High 🟩 🟩 🟩

Fewer surgical site infections

Surgical site infection (SSI, a wound infection after surgery) is the main outcome in contaminated abdominal operations. A 2026 network meta-analysis (NMA, a comparison across many trials) of 13 acid studies estimated lower infection odds than saline (Ayers et al., 2026). A randomized controlled trial (RCT, a trial that assigns people at random) found fewer infections after acid lavage (a wash) than after saline, with no attributed reactions (Singh et al., 2025). The meta-analysis authors are consultants, and the gain varies by operation.

Magnitude: In the 148-person trial, surgical site infection was 20.3% with hypochlorous acid lavage versus 39.2% with saline (absolute difference 19 percentage points). The network meta-analysis estimated that basic irrigation had about twice the odds of infection (odds ratio (OR, a comparison of odds) 1.97, 95% confidence interval (CI, the range consistent with the data) 1.13 to 3.44), described by the authors as about a 50% lower odds with the acid.

Medium 🟩 🟩

Faster early closure of clean acute wounds

In standardized suction-blister wounds on healthy forearms, a stabilized hypochlorous acid solution sped early closure compared with saline. The local account is fewer surface bacteria and less toxicity to the cells that close the wound than older chlorine solutions. One randomized trial in 20 volunteers found a day-4 advantage that had disappeared by day 10, when both wounds were essentially epithelialized (covered by new skin) (Burian et al., 2022). These were clean experimental wounds, not diabetic or venous ulcers, so the result does not by itself establish chronic-wound healing.

Magnitude: Re-epithelialization (new skin cover) on day 4 was 14% higher than saline (95% CI 6.8–20%) in 20 healthy volunteers. By day 10 the solutions were not different (0.3%, 95% CI −1.3 to 1.9%).

Periodontal plaque control after surgery

After open-flap periodontitis (gum disease) surgery, a hypochlorous acid rinse was compared with chlorhexidine (a standard antiseptic mouth rinse). The acid oxidizes pocket bacteria and stains less. In one 32-person trial, plaque-index reduction over 90 days was not inferior (not meaningfully worse on a preset test), and several pathogens recolonized at a similar rate (Plata et al., 2023). Another study found salivary counts down about 62–77%, a microbial result rather than attachment gain (Lin et al., 2023). One trial is a narrow base.

Magnitude: At day 21, plaque index was 22 ± 15 with hypochlorous acid versus 12 ± 7 with chlorhexidine in 32 people (more plaque remained in the acid arm at that visit), and reduction was not inferior across 7–90 days. Probing depth (the measured depth of the gum pocket) changed in both arms; equivalence between the rinses was not shown.

Healing of postsurgical diabetic foot lesions

Wide postsurgical lesions on the infected diabetic foot have been treated with a commercial super-oxidized solution (Dermacyn), a stabilized form of this acid. The proposed action is fewer wound bacteria than with povidone iodine (a standard skin antiseptic), alongside antibiotics and debridement (clearing of dead tissue). One randomized trial found a higher six-month healing rate with that solution than with povidone iodine, and fewer reinfections, with no added adverse events (Piaggesi et al., 2010). The sample is small, and this is not the acetic-acid combination used on chronic leg ulcers.

Magnitude: Healing at 6 months was 90% with the super-oxidized solution versus 55% with povidone iodine in 40 people.

Fewer inflammatory acne lesions

Inflammatory acne (red bumps and small pus-filled spots) has been treated with a super-oxidized solution made from saline. The proposed action is less surface bacteria than with no treatment, at a tolerability close to benzoyl peroxide (a standard acne treatment). One double-blind randomized trial found good improvement more often than with placebo and about as often as with benzoyl peroxide, and no systemic effects (Tirado-Sánchez & Ponce-Olivera, 2009). Nodular acne was excluded, and the sample is modest.

Magnitude: Good improvement was 54% (21 patients) with the super-oxidized solution versus 18% (4 patients) with placebo. The same rating was 50% with benzoyl peroxide.

Fewer central-line bloodstream infections

A dressing antiseptic that contains hypochlorous acid has been compared with povidone iodine on central venous catheters (intravenous lines placed in a large vein) in intensive care. The proposed action is fewer skin bacteria at the exit site. One randomized trial found fewer catheter-related bloodstream infections and fewer exit-site infection signs with the acid dressing than with povidone iodine (Yılmaz & İlgin, 2025). The sample is small, and this is exit-site care, not a systemic drug.

Magnitude: Catheter-related bloodstream infection and exit-site infection signs were lower with the hypochlorous-acid dressing than with povidone iodine in 60 intensive-care patients. The literature report no outcome figure as an infection percentage.

Itch relief in allergic eczema

Itch in allergic eczema is not only a mouse finding. An investigator-blinded randomized poster in 29 people found less itch at 72 hours with a topical acid gel than with no treatment (Berman & Nestor, 2017). A mouse study offers a nerve-calming account (Fukuyama et al., 2018). The human report is short, with an untreated control, and the poster was supported by Intraderm.

Magnitude: 73.7% of the treated group and 30% of the untreated group had less itch at 72 hours (19 treated, 10 untreated).

Low 🟩

Better eyelid scores in blepharitis ⚠️ Conflicted

Hypochlorous acid eyelid hygiene for blepharitis (chronic lid-margin inflammation) beat scrubs or wipes on lid or tear-film scores in two trials (Zhang et al., 2023; Mencucci et al., 2023). Cotton-pad use was not superior to saline on symptoms (Shi et al., 2026). Net: symptom benefit over saline is not consistent.

Magnitude: Ocular Surface Disease Index (a dry-eye symptom questionnaire) fell from 35.6 ± 19.3 to 15.3 ± 9.7 with 0.01% acid over 2 weeks (change −20.3 ± 20 versus −9.6 ± 15.3 with scrubs). Tear-film breakup lengthened only in the acid arm of a separate 4-week trial. A later trial did not show a significant symptom advantage over saline (Shi et al., 2026).

Chronic ulcer area with a combination solution

A small safety study of hypochlorous acid plus acetic acid saw ulcer area fall over five days (Fazli et al., 2024). A Cochrane review could not isolate healing for super-oxidized solutions (Dumville et al., 2017). The signal is human but indirect.

Magnitude: Median wound-area change over five days was −2.99 cm² with once-daily use and −10.48 cm² with twice-daily use in that ascending-dose series. There was no powered comparison of pure hypochlorous acid against usual chronic-ulcer care.

Nasal symptom scores ⚠️ Conflicted

Nasal hypochlorous acid rinses were compared with saline. One adult chronic-rhinosinusitis trial (nose and sinus inflammation) found lower symptom scores than saline (Yu et al., 2017). Nasal-allergy and pediatric trials found no symptom advantage (Kim et al., 2022; Cho et al., 2016). Net: symptom benefit over saline is not consistent.

Magnitude: In 43 adults, symptom scores were lower with the acid than with saline at 2 and 4 weeks. In the nasal-allergy trial (55 versus 59) and in children who finished a 4-week rinse, symptom scores did not differ from saline. The literature report no outcome figure as a point change on those scores.

Speculative 🟨

Slower aging from oral use

No human trial has tested this acid for lifespan, aging clocks, or death. Oral use for aging rests on chemistry, not on outcome data.

Fewer respiratory infections from inhaled use

No human outcome trial has tested inhaled acid against respiratory infections. A narrative review argues from mechanism (Winter et al., 2025), not from infection counts.

Benefit-Modifying Factors

  • Myeloperoxidase variants: Inherited differences in myeloperoxidase change how much acid neutrophils make. They have not been shown to change the response to a bottled topical solution.

  • Baseline bacterial load: Rinse studies found larger percentage drops when the starting salivary count was higher. A clean field has less room to move.

  • Sex: The trials cited here do not report a different benefit for women and men at the same topical concentration.

  • Diabetes and poor perfusion: Infected diabetic and ischemic (low-blood-flow) wounds are where an infection outcome matters most. They are also where an antiseptic rinse is least able to replace pressure relief and debridement.

  • Age: Older skin and poorer arterial flow slow closure. The same bottle strength was used across adult ages in the trials. Expectations for speed differ. The concentration does not.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: replicated human trials of stabilized hypochlorous acid do not show a clinical adverse-event excess over saline, and the serious tissue-injury literature is case material on concentrated sodium hypochlorite.

Medium 🟥 🟥

Local mouth effects after rinsing

After gum surgery, a hypochlorous acid mouth rinse was compared with chlorhexidine. The acid can leave a harsh feeling or dryness on the lining it touches, and it can change tooth color. In that trial the acid rinse was more often unpleasant than chlorhexidine, while taste change and tooth-color change were more often reported with chlorhexidine (Plata et al., 2023). These are local effects, not a circulating toxicity.

Magnitude: At day 21, an unpleasant feeling was reported by 93.7% with the hypochlorous acid rinse versus 56.2% with chlorhexidine. Mucosal dryness was 43.7% at day 7 with the 0.05% rinse. Tooth-color change at day 21 was 31.25% with the acid versus 68.75% with chlorhexidine.

Low 🟥

Chemical injury when sodium hypochlorite is substituted

Concentrated sodium hypochlorite can injure tissue when used as if it were a mild wound acid. Dental case reports describe pain, swelling, and local damage (Inchingolo et al., 2025). Stabilized hypochlorous acid trials have not shown that injury. The evidence concerns a different chemical.

Magnitude: Not quantified in available studies. The reports describe individual injuries after concentrated sodium hypochlorite extrusion, not an incidence for stabilized hypochlorous acid on skin, eyelids, or wounds.

Speculative 🟨

Oxidant contact from oral or inhaled unstudied doses

No controlled human study has measured harm from oral or inhaled use of dilute stabilized solutions sold for longevity. The concern is mechanistic only: the acid oxidizes the first proteins it contacts.

Risk-Modifying Factors

  • Concentration and pH: Alkaline, high-strength hypochlorite is the form tied to tissue injury. Mildly acidic, parts-per-million acid is the form in the tolerability trials.

  • Baseline open tissue: A deep or heavily contaminated field sees more of any irrigant. That raises both the chance of benefit and the chance of stinging if the wrong bottle is used.

  • Baseline biomarkers: No blood test is described as changing the risk of topical stabilized acid. Open tissue, not a lab value, is the baseline that changes how much solution touches living tissue.

  • Sex: No sex difference in adverse events is described for topical stabilized acid.

  • Prior skin or eye disease: A broken skin barrier or an already inflamed eye has less reserve if a non-matched formula is applied. Intact skin in the volunteer wound model tolerated the stabilized acid.

  • Age: Thinner older skin and the ocular surface in later life are less forgiving of a mix-up with bleach. The stabilized-acid trials did not flag a separate older-adult adverse-event pattern.

Key Interactions & Contraindications

  • Other chlorine products and ammonia: Mixing with household bleach, ammonia, or acids can release irritating chlorine gas. Severity: absolute avoidance of mixing. Consequence: airway and eye irritation. Mitigation: use one product, then rinse the field with saline before anything else.

  • Other topical antiseptics: Chlorhexidine, povidone-iodine, and silver dressings can inactivate the acid or add irritation. Severity: caution. Consequence: less antimicrobial effect or stacked stinging. Mitigation: let the surface dry and separate the applications.

  • Antioxidant topicals: Ascorbic acid serums and other strong reducing agents quench hypochlorous acid on contact. Severity: caution. Consequence: loss of antiseptic effect at that site. Mitigation: separate them in time.

  • Systemic drugs: No cytochrome P450 interaction is expected, because the acid is consumed on the surface and does not circulate as a parent drug. Severity: none established. Consequence: none described for oral drugs such as statins or anticoagulants.

  • Over-the-counter bleach and pool chlorine: These are sodium hypochlorite or other chlorine releasers, not a wound rinse. Severity: absolute on tissue. Consequence: chemical burn. Mitigation: a label that names hypochlorous acid well under 0.1%, not cleaning bleach near 5%.

Populations who should avoid Hypochlorous Acid:

  • People who would use it as an oral beverage. No oral dose for healthspan is established. Severity: avoid. Consequence: unstudied oxidant contact with the gut lining.
  • Anyone applying a non-ophthalmic wound solution into the eye. Severity: avoid. Consequence: stinging from the wrong acidity or extra ingredients.
  • Anyone with a prior localized reaction to that specific formulation. Severity: avoid. Consequence: repeat irritation.
  • Use of cleaning-strength sodium hypochlorite (label strength near 5%) on tissue. Severity: absolute. Consequence: chemical injury. No liver, kidney, or heart-failure class cutoff is defined, because topical acid does not produce a circulating dose those classes were built for.

Risk Mitigation Strategies

  • Site-matched bottle: Wound solution stays on wounds. Ophthalmic acid stays on lids. That separation limits stinging from the wrong acidity or extra ingredients.

  • Household bleach kept out: Cleaning-strength sodium hypochlorite (near 5%) is a different chemical. Keeping it out of the regimen prevents the chemical injury described in extrusion reports.

  • Rinse not administered orally: Mouth regimens in trials were not administered orally. That avoids unstudied oxidant contact with the gut.

  • Other antiseptics separated in time: The field is left to dry before chlorhexidine, povidone-iodine, or silver. That limits inactivation and stacked irritation.

  • Expired solution set aside: Stabilized acid loses activity with light, heat, and time. A dated, light-protected bottle prevents reliance on an inactive solution.

  • Rising pain as a stop cue: Wound trials found pain similar to saline. Rising pain is a cue to stop and check for the wrong product or a spreading infection, which limits ongoing chemical irritation.

Therapeutic Protocol

  • Surgical lavage: In one contaminated-abdomen trial, hypochlorous acid was a single peritoneal (abdominal-cavity) wash before closure, compared with saline, not a take-home course.

  • Eyelid hygiene: Trials used 0.01% acid on the lid margin for 2–4 weeks, with warm compresses, and scored the lids at the end of that window.

  • Periodontal rinse: After flap surgery, 0.05% then 0.025% acid for 21 days was compared with chlorhexidine, without ordinary brushing during that window.

  • Nasal rinse: Trials rinsed the nose with dilute acid for 4 weeks in nasal allergy and for 4–8 weeks in chronic sinus symptoms, compared with saline.

  • Time of day: No circadian advantage is described. Eyelid and oral trial regimens were repeated across the day, not tied to morning or night.

  • Half-life in the body: The acid is consumed by local tissue within seconds. There is no circulating half-life to schedule around.

  • Single versus repeated exposure: Surgery trials used one wash. Experimental wounds were treated on days 0, 2, and 4. Eyelid and mouth uses were repeated over weeks.

  • Genetic variants: Myeloperoxidase variants change endogenous production. None is shown to set the topical concentration.

  • Sex: Reports do not describe a different concentration for women and men.

  • Age: Older or ischemic skin closes more slowly. Trial concentrations were not changed for age. The expected pace of closure was.

  • Baseline bacterial load: Percentage drops in saliva were larger when the starting count was higher. A clean field moves less.

  • Existing disease: Diabetes, poor arterial flow, and heavy biofilm are where infection outcomes matter, and where a rinse does not replace debridement or pressure relief.

  • Diabetic foot lesions: One trial applied a commercial super-oxidized solution to wide postsurgical diabetic foot wounds and followed healing weekly for 6 months.

  • Inflammatory acne: One trial compared a super-oxidized solution with benzoyl peroxide and with placebo for mild to moderate inflammatory acne.

  • Regimen sources: Dakin and Carrel popularized chlorine wound irrigation. Eyelid use follows ophthalmology hygiene trials. Plata set the dental rinse, Yu the nasal rinse, Piaggesi (Dermacyn) the diabetic-foot wash, and Tirado-Sánchez the acne regimen.

Discontinuation & Cycling

  • Course length: Surgical, wound, and post-gum-surgery uses are short-term, for the episode of care, not a lifelong systemic therapy.

  • Withdrawal: No withdrawal syndrome is described after topical applications stop.

  • Taper: No taper is described. Applications end when the local indication ends.

  • Cycling: Cycling to preserve an effect is not described. Blepharitis regimens in trials ran 2–4 continuous weeks.

Sourcing and Quality

  • Device versus cosmetic mist: Many wound cleansers are cleared devices under the Food and Drug Administration (FDA, the United States regulator). A stated concentration and a pH at or below about 7 keep the acid, not hypochlorite, dominant.

  • Stability: Light-protected, dated bottles match the stabilized products in trials. Fresh electrolyzed water with no shelf claim can decay before it is used.

  • Not bleach: Household sodium hypochlorite is more alkaline and more destructive on tissue. The matching label names hypochlorous acid.

  • Names in the clinical record: Vashe appears as a wound solution, and ophthalmic hypochlorous acid solutions appear in eyelid trials. Microcyn is the core in one dermatology report. Supplement seals rarely apply. These are devices or cosmetics, not dietary supplements.

  • Countertop generators: Home electrolysis units vary in pH and parts per million. They are not the same object as a cleared wound solution with a dated assay.

Practical Considerations

  • Time to effect: Surface bacteria fall at the time of application. A re-epithelialization difference was measured at day 4 in experimental wounds. Eyelid scores were rechecked at 2–4 weeks. Surgical infection was counted out to 30 days.

  • Pitfalls: Treating bleach as if it were this acid. Expecting a longevity effect from oral use. Using an expired bottle. Judging success by odor instead of wound size or a symptom score.

  • Regulatory status: In the United States the usual path is device clearance as a topical wound cleanser, not an approval as a drug to extend lifespan or as an oral longevity product.

  • Cost and access: Ready-to-use bottles are widely sold and are not in the cost range of rare biologics. Operating-room lavage is part of a procedure rather than a standalone expensive drug.

Interaction with Foundational Habits

  • Sleep: Direction: none established. Topical acid does not enter a pathway known to change sleep structure. Evening eyelid use in blepharitis care has not been reported to fragment sleep. No bedtime rule is described.

  • Nutrition: Direction: none. The acid is not a nutrient and has no reported vitamin-depletion balance. Mouth rinses in the trials were not administered orally, so they are not a feeding, and food timing is not an absorption question.

  • Exercise: Direction: none on training adaptation. Nothing links the acid to blunted muscle growth or to a required workout gap. A lower-limb ulcer dressing can limit impact exercise because of the wound, not because of a drug effect on muscle.

  • Stress management: Direction: none direct. Neutrophils make more acid during infection, which is an immune event, not a cortisol lever. Topical use does not treat stress, and stress-reduction practices do not replace irrigation of an infected wound.

Monitoring Protocol & Defining Success

Baseline assessment is a clinical inspection, not a blood panel. Topical hypochlorous acid does not circulate as a parent drug, so liver enzymes, kidney filtration, and blood counts do not track an effect. Before a wound course the baseline is area, pus, odor, spreading redness, and pain. Before eyelid use, a symptom score and the lid margin are the comparison. Periodontal baselines are the plaque and gingival (gum) indexes. Before a nasal rinse, a sinus or nasal-allergy symptom score is the comparison.

Ongoing checks follow trial windows rather than a laboratory calendar. Experimental wounds were remeasured within 10 days, eyelids at 2 or 4 weeks, peritonitis (abdominal-lining infection) wounds at days 15 and 30, and periodontal indexes at 7, 21, and 90 days. A comparison at 1–2 weeks and again near 4 weeks matches that pattern, earlier if pain or redness spreads.

  • Wound comfort, odor, and drainage across the day.
  • Itch or lid crusting if the acid is used on the eyelids.
  • Taste change or mucosal soreness if a mouth rinse is used and not administered orally.
  • Whether the container is still in date. An inactive solution looks like a failed response.
Biomarker Optimal Functional Range Why Measure It? Context/Notes
Wound surface area No universal lab range. Track closure, or a steady fall from that person’s own baseline Shows whether the wound is closing Photograph in the same light. Conventional clinic charts often record area without a “normal” blood-style range
Local infection signs No pus, no spreading redness, no new odor Catches infection the acid did not control Rising pain with fever is a clinical event, not a concentration target
Ocular symptom score Falling score from that person’s baseline. No single optimal number across questionnaires Tracks blepharitis symptoms Ocular Surface Disease Index (OSDI, a dry-eye symptom questionnaire) was the score in one eyelid trial. Conventional “normal” cutoffs differ by form and are not a drug level
Plaque or gingival index Falling index from baseline toward the low end of the scale in use Tracks the periodontal target Indexes are clinical scores, not blood tests. No fasting or time-of-day rule

Emerging Research

  • Vascular graft infection: NCT07678632 is a not-yet-recruiting pilot of hypochlorous acid wash at prosthetic bypass, planned for about 500 people, with graft infection followed for 12 months. A clear drop would extend the surgical-infection finding. A null result would narrow it.

  • Diabetic foot closure: NCT06908148 (about 200 people, not yet recruiting) compares electrolyzed water with usual care. NCT05132179 (about 202, recruiting) is registered as hypochlorous acid versus polyhexanide (another wound antiseptic) but also names Dakin’s solution. Either result could move a still-thin healing claim (Dumville et al., 2017).

  • Venous leg ulcers: NCT07440797 plans about 102 people, not yet recruiting, comparing Vashe with saline on inflamed venous or mixed leg ulcers. The endpoint is inflammatory signs of heavy bacterial load, which speaks to infection control more than to lifespan.

  • Inhaled or oral longevity use: No registered trial is testing death, aging clocks, or healthy lifespan. A narrative review argues for respiratory antisepsis (Winter et al., 2025). An outcome trial in either direction would move that claim off a mechanistic footing. Until then it stays speculative.

Conclusion

Hypochlorous acid is a short-lived chlorine chemical that white blood cells already make to damage microbes. Bottled solutions put that chemistry on skin, wounds, eyelids, the mouth, and the nose. Washing at surgery is associated with fewer wound infections than saline. Clean experimental wounds close faster early on. Eyelid scores improved against other lid hygiene in some comparisons and not against saline in another. After gum surgery, plaque control matches a standard antiseptic rinse. Postsurgical diabetic foot lesions and inflammatory acne improved in single comparisons. Nasal rinses beat saline for chronic sinus symptoms in one comparison and not for nasal allergy or in children. No study has followed aging, death, or a biological age measure.

Harms of the stabilized acid look small on wounds and eyelids. Those trials report comfort similar to saline. A mouth rinse was more often unpleasant than a standard antiseptic. The serious burns in the chlorine literature come from concentrated bleach, a different and harsher chemical, and the two are not interchangeable. Oral or inhaled use in the hope of slowing aging is a marketing idea without a human outcome behind it, and the molecule damages whatever surface it hits first.

The record is strongest on a surgical wound and weakest where a longevity claim would have to live. Some combined surgery evidence was assembled by consultants, so the infection finding sits against that source mix. Cost is modest. The evidence supports a topical antiseptic with a favorable local safety picture, not a longevity drug.

Top - Benefits - Risks - Protocol